Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Mar 14, 2014

Keywords

ClinConnect Summary

This clinical trial is researching how to better treat advanced cancer using a method called high-throughput sequencing, which involves analyzing the genetic makeup of tumors. The goal is to understand the unique characteristics of each patient's cancer to provide more personalized treatment options. The trial is currently looking for participants, specifically adults aged 65 to 74 who have been diagnosed with any type of cancer.

To be eligible, patients must have a tumor that can be tested, either through a biopsy (a small tissue sample) or other types of tissue that can help in understanding their cancer better. Participants will need to provide consent before any procedures, and the trial aims to be inclusive, welcoming women and people from diverse backgrounds. If you choose to participate, you can expect to undergo some routine procedures, during which leftover tissue may be used for research. It's important to note that if a doctor believes a patient is not fit for the biopsy, they will not be allowed to join the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. A histologically or cytologically confirmed diagnosis of cancer
• • 2. Patients with any malignancy.
• • 3. Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation.
• • OR Patients are undergoing standard of care surgeries or procedures where fresh specimens will be first used for routine pathologic assessment and only then will leftover tissue be used for research purposes.
• • 4. Procedure-specific signed informed consent prior to initiation of any study-related procedures.
• • 5. Women and minorities are included in this protocol.
• • 6. Patients with multiple malignancies remain eligible.
• • 7. Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible.
• Exclusion Criteria:
• • 1. It is the enrolling study physicians discretion to decide if a patient is not fit enough to undergo tissue biopsy.
• • 2. Patients who are incarcerated are not eligible to participate.